12/09/2025
Worth watching
A recent report highlighted the work of physician and researcher Dr. Patrick Soon-Shiong and his development of an immunotherapy called Anktiva. The approach centers on activating the body’s natural killer (NK) cells rather than using traditional chemotherapy to help the immune system better recognize and target cancer cells. Anktiva is currently approved by the FDA for one form of bladder cancer, and ongoing studies are exploring its use in additional conditions.
According to the report, Soon-Shiong and his team believe that NK cells, when stimulated with IL-15, may play a stronger role in antitumor activity than previously recognized. They point to cases in which patients lived longer than expected after standard treatments were no longer effective.
Critics, however, caution that broader claims about the therapy go beyond existing evidence, emphasizing the need for large, randomized clinical trials to confirm safety and effectiveness across different cancer types.
Soon-Shiong’s team says they have treated more than 1,000 patients in research settings including individuals with metastatic pancreatic cancer and recurrent HPV-positive throat cancer and have observed encouraging responses in some cases. The ongoing discussion reflects a tension between scientific enthusiasm for emerging therapies and the regulatory processes designed to ensure rigorous evaluation before wider access is granted.